Neutralising antibody molecules having specificity for human IL-17
View Patent ↗The invention relates to an antibody molecule having specificity for antigenic determinants of IL-17, therapeutic uses of the antibody molecule and methods for producing said antibody molecule.
1. A neutralising antibody having specificity for human IL-17, wherein the antibody binds the same epitope as an antibody comprising a light chain and a heavy chain, wherein the variable domain of the heavy chain comprises SEQ ID NO:5 for CDR-H1, SEQ ID NO:6 for CDR-H2, and SEQ ID NO:7 for CDR-H3 and wherein the variable domain of the light chain comprises SEQ ID NO:8 for CDRL1, SEQ ID NO:9 for CDR-L2, and SEQ ID NO:10 for CDR-L3.
2. The neutralising antibody having specificity for human IL-17 according to claim 1 , wherein the antibody cross-blocks the binding of an antibody in which the variable domain of the heavy chain comprises the sequence gH11 (SEQ ID NO: 11) and the variable domain of the light chain comprises the sequence gL3 (SEQ ID NO: 13) to human IL-17.
3. The neutralising antibody having specificity for human IL-17 according to claim 1 , wherein the antibody cross-blocks the binding of an antibody in which the variable domain of the heavy chain comprises SEQ ID NO:5 for CDR-H1, SEQ ID NO:6 for CDR-H2, and SEQ ID NO:7 for CDR-H3 and wherein the variable domain of the light chain comprises SEQ ID NO:8 for CDRL1, SEQ ID NO:9 for CDR-L2, and SEQ ID NO:10 for CDR-L3 to human IL-17.
4. The neutralising antibody having specificity for human IL-17, according to any one of claims 1 , 2 and 3 , wherein the antibody affinity for human IL-17 is between 100 pM and 400 pM.
5. The neutralising antibody having specificity for human IL-17, according to any one of claims 1 , 2 and 3 , wherein the antibody affinity for human IL-17 is less than 500 pM.
6. The neutralising antibody having specificity for human IL-17 according to claim 1 , wherein one or more effector molecules are attached to said antibody.
7. A pharmaceutical composition comprising the antibody according to claim 1 .